CRL Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
982.7M
-2.1%
1.0B
+0.8%
995.8M
+0.2%
994.2M
-1.1%
1.0B
Cost of Revenue
624.9M
-2.5%
640.7M
-8.6%
701.2M
+2.4%
684.5M
+2.8%
666.1M
Gross Profit
357.9M
-1.5%
363.4M
+23.3%
294.7M
-4.9%
309.7M
-8.6%
338.8M
Operating Expenses
155.2M
-36.2%
243.5M
+39.3%
174.8M
-70.5%
593.1M
+189.3%
205.0M
R&D
0
0
0
0
0
SG&A
140.6M
-38.6%
228.9M
+43.6%
159.4M
-18.7%
196.1M
+10.4%
177.6M
Operating Income
202.6M
+69.0%
119.9M
-0.0%
119.9M
+142.3%
-283440000
-311.8%
133.8M
EBITDA
274.9M
+46.9%
187.2M
+0.1%
187.0M
+9.5%
170.8M
-22.0%
219.0M
Net Income
334.4M
+44105.8%
-760000
+94.9%
-14802000
+94.6%
-276290000
-597.3%
55.6M
EPS (Basic)
$6.97
+23333.3%
$-0.03
+90.0%
$-0.30
+94.7%
$-5.62
-606.3%
$1.11
EPS (Diluted)
$6.86
+22966.7%
$-0.03
+90.0%
$-0.30
+94.7%
$-5.68
-616.4%
$1.10
Shares (Diluted)
48.6M
+1.2%
48.0M
-1.9%
49.0M
+0.6%
48.7M
-1.5%
49.4M
Charles River Laboratories International (CRL) — Financials